Junctional Epidermolysis Bullosa 2 (JEB2)
Gene or Region: LAMA3
Reference Variant: no change in LAMA3
Mutant Variant: 6,589 bp deletion
Affected Breeds: American Saddlebred
Research Confidence: High - Findings reproduced multiple studies
Explanation of Results: jeb2/jeb2 = homozygous for Junctional Epidermolysis Bullosa Type 2, trait expressed jeb2/n = heterozygous for Junctional Epidermolysis Bullosa Type 2, carrier n/n = no variant detected
JEB2 in American Saddlebreds: Understanding Junctional Epidermolysis Bullosa & LAMA3 Mutation
Junctional Epidermolysis Bullosa 2 (JEB2), also known as red foot disease or hairless foal syndrome, results in the inability to produce the proteins needed to keep the skin on the body. Affected foals exhibit symptoms within days of birth, including blisters at the pressure points, detachment of the hooves, and oral ulcers. As there is no treatment, affected foals are humanely euthanized. JEB2 is an autosomal recessive condition, thus a horse must inherit two copies of the allele (jeb2/jeb2) to show any signs. Horses with only one copy of the variant (jeb2/n) are known as carriers due to their ability to produce affected foals.
Gene Information
LAMA3 is a subunit of a key component of basement membranes. Mutations in other subunits of this complex have been shown to result in JEB2 in many human populations. This particular mutation is a 6,589 bp deletion spanning exons 24-27 that disrupts the normal amino acid sequence, resulting in a truncated protein.
Carrier frequency: estimated at slightly more than 5% in American Saddlebreds
References
K. T. Graves, P. J. Henney and R. B. Ennis. Partial deletion of the LAMA3 gene is responsible for hereditary junctional epidermolysis bullosa in the American Saddlebred Horse. (2008) Animal Genetics, 40, 35–41
More Horse Health
Foal Immunodeficiency Syndrome
Foal immunodeficiency syndrome (FIS) is a failure in the development of the adaptive immune system. At 3-6 weeks of age, once the maternal antibodies begin to degrade, foals exhibit signs of anemia, diarrhea, and pneumonia. As these foals fail to respond to treatment for infections, they are humanely euthanized at a young age.
Glanzmann Thrombasthenia
Glanzmann Thrombasthenia (GT) is a blood platelet function disorder, resulting from a reduction in the platelet fibrinogen receptor protein. Clinical signs can be characterized by bleeding on the skin or from the mouth/nostril/gastrointestinal mucosas, and may include skin rashes with blood spots under the skin, nasal bleeding, gastrointestinal and gingival bleedings.
Glycogen Branching Enzyme Deficiency
Glycogen Branching Enzyme Deficiency (GBED) is a lethal recessive disorder characterized by seizures, muscle weakness, respiratory failure, and death. Many affected foals do not make it full term and are aborted or stillborn. Carriers (gbed/n) have no known issues.